J Curr Surg

Journal of Current Surgery, ISSN 1927-1298 print, 1927-1301 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Curr Surg and Elmer Press Inc

Journal website http://www.currentsurgery.org

Original Article

Volume 4, Number 1, February 2014, pages 10-16

Non-Sentinel Lymph Node Metastasis is Hard to Predict by Clinicopathological Factors if SLN Metastasis in Two or Fewer Nodes in Breast Cancer

**Table 1.** Association Between SLN Metastasis and Clinicopathological Features (n = 176)
	Total	SLN	P value
SLN: sentinel lymph node; LVI: lymphovascular involvement; ER: estrogen receptor; PR: progesterone receptor.
Age				0.0231
≤ 50	59	44 (74.6)	15 (25.4)
> 50	117	103 (88.0)	14 (12.0)
Tumor size				0.0039
T1	138	122 (88.4)	16 (11.6)
T2	32	21 (65.6)	11 (34.4)
T3	6	4 (66.7)	2 (33.3)
Histological grade				0.8171
I	122	103 (84.4)	19 (15.6)
II	30	25 (83.3)	5 (16.7)
III	24	19 (79.2)	5 (20.8)
LVI				0.0002
Negative	163	141 (86.5)	22 (13.5)
Positive	13	6 (46.2)	7 (53.8)
ER and/or PR				0.4591
Negative	19	17 (89.5)	2 (10.5)
Positive	157	130 (82.8)	27 (17.2)
HER2				0.0859
Negative	122	98 (80.3)	24 (19.7)
Positive	54	49 (90.7)	5 (9.3)
Molecular subtypes				0.2965
Luminal A	72	56 (77.8)	16 (22.2)
Luminal B	85	74 (87.1)	11 (12.9)
HER2	6	6 (100)	0 (0)
Triple negative	13	11 (84.6)	2 (15.4)
Ki-67				0.3388
Ki-67 < 14%	95	77 (81.1)	18 (18.9)
Ki-67 ≥ 14%	81	70 (86.4)	11 (13.6)

Table 1. Association Between SLN Metastasis and Clinicopathological Features (n = 176)

Total

SLN

P value

Negative (%)

Positive (%)

SLN: sentinel lymph node; LVI: lymphovascular involvement; ER: estrogen receptor; PR: progesterone receptor.

Age

0.0231

≤ 50

44 (74.6)

15 (25.4)

> 50

117

103 (88.0)

14 (12.0)

Tumor size

0.0039

138

122 (88.4)

16 (11.6)

21 (65.6)

11 (34.4)

4 (66.7)

2 (33.3)

Histological grade

0.8171

122

103 (84.4)

19 (15.6)

25 (83.3)

5 (16.7)

III

19 (79.2)

5 (20.8)

LVI

0.0002

Negative

163

141 (86.5)

22 (13.5)

Positive

6 (46.2)

7 (53.8)

ER and/or PR

0.4591

Negative

17 (89.5)

2 (10.5)

Positive

157

130 (82.8)

27 (17.2)

HER2

0.0859

Negative

122

98 (80.3)

24 (19.7)

Positive

49 (90.7)

5 (9.3)

Molecular subtypes

0.2965

Luminal A

56 (77.8)

16 (22.2)

Luminal B

74 (87.1)

11 (12.9)

HER2

6 (100)

0 (0)

Triple negative

11 (84.6)

2 (15.4)

Ki-67

0.3388

Ki-67 < 14%

77 (81.1)

18 (18.9)

Ki-67 ≥ 14%

70 (86.4)

11 (13.6)

**Table 2.** Multivariate Analysis of Clinicopathologic Factors
		P value	RR (95% CI)
RR: relative risk; CI: confidence interval; LVI: lymphovascular involvement.
Age	> 50 vs. ≤ 50	0.043	2.541 (1.029 - 6.274)
Tumor size	T1 vs T2, T3	0.004	4.066 (1.569 - 10.533)
LVI	(-)ve vs. (+)ve	0.015	4.924 (1.367 - 17.744)

Table 2. Multivariate Analysis of Clinicopathologic Factors

P value

RR (95% CI)

RR: relative risk; CI: confidence interval; LVI: lymphovascular involvement.

Age

> 50 vs. ≤ 50

0.043

2.541 (1.029 - 6.274)

Tumor size

T1 vs T2, T3

0.004

4.066 (1.569 - 10.533)

LVI

(-)ve vs. (+)ve

0.015

4.924 (1.367 - 17.744)

**Table 3.** Association Between SLN Metastasis and Non-SLN Metastasis (n = 29)
	Total	Number of non-SLN metastasis (%)	P value
SLN metastasis						0.1787
1 node	20	13 (65.0)	5 (25.0)	0 (0)	2(10.0)
2 nodes	5	3 (60.0)	1 (20.0)	0 (0)	1 (20.0)
≥ 3 nodes	4	1 (25.0)	2 (50.0)	1 (25.0)	0 (0)

Table 3. Association Between SLN Metastasis and Non-SLN Metastasis (n = 29)

Total

Number of non-SLN metastasis (%)

P value

≥ 3

SLN metastasis

0.1787

1 node

13 (65.0)

5 (25.0)

0 (0)

2(10.0)

2 nodes

3 (60.0)

1 (20.0)

0 (0)

1 (20.0)

≥ 3 nodes

1 (25.0)

2 (50.0)

1 (25.0)

0 (0)

**Table 4.** Association Between Non-SLN Metastasis and Clinicopathological Features (n = 29)
	Total	SLN	P value
SLN: sentinel lymph node; LVI: lymphovascular involvement; ER: estrogen receptor; PR: progesterone receptor.
Age				0.3625
≤ 50	15	10 (66.7)	5 (33.3)
> 50	14	7 (50.0)	7 (50.0)
Tumor size				0.8888
T1	16	10 (62.5)	6 (37.5)
T2	11	6 (54.5)	5 (45.5)
T3	2	1 (50.0)	1 (50.0)
Histological grade				0.0618
I	19	14 (73.7)	5 (26.3)
II	5	1 (20.0)	4 (80.0)
III	5	2 (40.0)	3 (60.0)
LVI				0.0638
Negative	22	15 (68.2)	7 (31.8)
Positive	7	2 (28.6)	5 (71.4)
ER and/or PR				0.7975
Negative	2	1 (50.0)	1 (50.0)
Positive	27	16 (59.3)	11(40.7)
HER2				0.3527
Negative	24	15 (62.5)	9 (37.5)
Positive	5	2 (40.0)	3 (60.0)
Molecular subtypes				0.8888
Luminal A	16	10 (62.5)	6 (37.5)
Luminal B	11	6 (54.5)	5 (45.5)
HER2	2	1 (50.0)	1 (50.0)
Triple negative				0.7276
Ki-67
Ki-67 < 14%	18	11 (61.1)	7 (38.9)
Ki-67 ≥ 14%	11	6 (54.5)	5 (45.5)

Table 4. Association Between Non-SLN Metastasis and Clinicopathological Features (n = 29)

Total

SLN

P value

Negative (%)

Positive (%)

SLN: sentinel lymph node; LVI: lymphovascular involvement; ER: estrogen receptor; PR: progesterone receptor.

Age

0.3625

≤ 50

10 (66.7)

5 (33.3)

> 50

7 (50.0)

Tumor size

0.8888

10 (62.5)

6 (37.5)

6 (54.5)

5 (45.5)

1 (50.0)

Histological grade

0.0618

14 (73.7)

5 (26.3)

1 (20.0)

4 (80.0)

III

2 (40.0)

3 (60.0)

LVI

0.0638

Negative

15 (68.2)

7 (31.8)

Positive

2 (28.6)

5 (71.4)

ER and/or PR

0.7975

Negative

1 (50.0)

Positive

16 (59.3)

11(40.7)

HER2

0.3527

Negative

15 (62.5)

9 (37.5)

Positive

2 (40.0)

3 (60.0)

Molecular subtypes

0.8888

Luminal A

10 (62.5)

6 (37.5)

Luminal B

6 (54.5)

5 (45.5)

HER2

1 (50.0)

Triple negative

0.7276

Ki-67

Ki-67 < 14%

11 (61.1)

7 (38.9)

Ki-67 ≥ 14%

6 (54.5)

5 (45.5)